近5年高被引文献
Human Inborn Errors of Immunity: 2022 Update on the Classification from the International Union of Immunological Societies Expert Committee
article
Full Text
OpenAlex
918
FWCI101.035
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study
article
Full Text
OpenAlex
390
FWCI61.432
The 2022 Update of IUIS Phenotypical Classification for Human Inborn Errors of Immunity
article
Full Text
OpenAlex
383
FWCI42.488
X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19
article
Full Text
OpenAlex
366
FWCI58.206
Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
article
Full Text
OpenAlex
318
FWCI70
Bimekizumab versus Secukinumab in Plaque Psoriasis
article
Full Text
OpenAlex
305
FWCI24.061
Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials
article
Full Text
OpenAlex
288
FWCI49.844
Preexisting autoantibodies to type I IFNs underlie critical COVID-19 pneumonia in patients with APS-1
article
Full Text
OpenAlex
268
FWCI34.964
Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD
article
Full Text
OpenAlex
268
FWCI17.142